StockNews.AI
FLGT
StockNews.AI
194 days

Fulgent to Announce Fourth Quarter and Full Year 2024 Financial Results on Friday, February 28, 2025

1. Fulgent Genetics to announce Q4 2024 results on February 28, 2025. 2. Management will host a conference call for analysts and investors post-results. 3. Company focuses on integrating lab services with therapeutic drug development. 4. They are targeting improvements in cancer treatment through novel technologies.

Earnings
-2.6%Current Return
VS
-1%S&P 500
$16.5702/06 04:16 PM EDTEvent Start
$16.1402/07 10:50 PM EDTLatest Updated
3m saved
Insight
Article

FAQ

Why Neutral?

While the announcement of results could influence FLGT's stock, it is routine in nature. Such earnings releases have historically shown varied immediate impacts, depending on performance and forecasts.

How important is it?

This announcement is significant for stakeholders tracking FLGT's transition into precision medicine, but usual in the earnings cycle. Key metrics from this earnings call will provide insight into the company's trajectory.

Why Short Term?

Market reactions typically occur right after earnings calls. Past examples show stock price movements are most relevant around earnings reporting dates.

Related Companies

FLGT
EL MONTE, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced that it will release its fourth quarter and full year 2024 financial results before the market opens on Friday, February 28, 2025. Management will host a conference call for the investment community the same day at 8:30 AM ET (5:30 AM PT) to discuss the results and answer questions. The call may be accessed through a live audio webcast on the Investor Relations section of the Company’s website, http://ir.fulgentgenetics.com. An audio replay will be available at the same location. About Fulgent Fulgent is a technology-based company with a well-established laboratory services business and a therapeutic development business. Fulgent’s laboratory services business, which was formerly referred to as the clinical diagnostic business, includes technical laboratory services and professional interpretation of laboratory results by licensed physicians. Fulgent’s therapeutic development business is focused on developing drug candidates for treating a broad range of cancers using a novel nanoencapsulation and targeted therapy platform designed to improve the therapeutic window and pharmacokinetic profile of new and existing cancer drugs. The Company aims to transform from a genomic diagnostic business into a fully integrated precision medicine company.

Related News